Vol 47 No 9

Earlier in 2019, the AUA and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction published a joint guideline on the subject of incontinence after prostate treatment. In this interview, Jaspreet S. Sandhu, MD, a member of this guideline’s panel, explains the rationale behind the guideline and summarizes its key points.

A preliminary study of the use of salvage lymph node dissection in patients with nonmetastatic, castration-resistant prostate cancer indicates the potential to delay disease recurrence as well as the use of systemic therapies through this approach.

"We have entered a renaissance in the care for patients with benign prostatic hyperplasia-related lower urinary tract symptoms," writes Steven A. Kaplan, MD.

A new study suggests that prostate-specific membrane antigen positron emission tomography/computed tomography may be a highly beneficial tool for initial staging of high-risk and high-intermediate-risk prostate cancer.

Researchers say the use of apalutamide (Erleada) in patients with high-risk, nonmetastatic castration-resistant prostate cancer improves metastasis-free survival in patients who have previously undergone radical prostatectomy or external radiotherapy-regardless of the type of treatment they received.

"The last several years have been particularly exciting in the area of metastatic castrate-resistant prostate cancer," writes J. Brantley Thrasher, MD.

Analyses of data collected in PROCEED, a large real-world registry, corroborate phase III study findings demonstrating that sipuleucel-T (Provenge) treatment for metastatic castrate-resistant prostate cancer has a particular benefit for improving overall survival in African-American men.

"One is the delay in delivering care. If I order surgery that requires prior authorization, it won’t always come through in a timely manner, and that impacts patients’ quality of life," says one urologist.

"Patient access to health information-whether it resides in a medical record, a lab company’s system, or an insurance company records-is a right firmly protected by federal laws and regulations," writes Robert A. Dowling, MD.

Patients with CVD taking abiraterone or enzalutamide have a 43% higher risk of hospitalization, according to a recent study.

A survey of low-risk prostate cancer patients found men who choose active surveillance over definitive treatment have similar mental health outcomes.

Trusts provide management of assets while minimizing probate expenses, according to Jeff Witz, CFP.

Willie Underwood, III, MD, MSc, MPH, the Buffalo, NY urologist elected to the American Medical Association’s Board of Trustees in June, believes physicians must step up and help influence governmental decisions designed to improve and expand health care for all Americans.